Monday, July 07, 2014 1:58:17 PM
Decision making within the hospital/physician environment takes into consideration efficacy, safety, outcomes, and cost. If a drug/device/surgical platform is able to show parity relative to a similar modality, than cost and physician confidence will drive utilization. In this instance, the level of disdain for the ISRG approach, coupled with a very real niche marketplace in community hospitals, and ambulatory surgery centers, positions Titan extremely well. Not to mention the hospitals who are going to invest in the alternative.
I don't see the need for multiple Titan units - somewhat defeats the purpose of their approach, don't you think? Surgeons have been driving this development from day 1, MIS is here to stay, its due to physician driven feedback and design.
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM